Clear responder, partial responder, non-responder — each gets a different next move.
Week 10 labs are not a verdict. They're a sampling point on a curve, and the curve has three common shapes. If you treat all three the same way — "keep going, dose up" — you'll either burn out a responder, plateau a partial, or compound a non-responder's metabolic wreckage. The practitioner corpus is consistent on this: the Week 10 read is where the protocol bifurcates. You don't escalate blind. You read the trajectory, classify the response, and switch lanes.
Mechanism: why Week 10 separates the shapes
By Week 10 of a GLP-1 + supporting-stack protocol, three things have happened biologically. First, GLP-1 receptor signaling has been pharmacologically saturated for long enough that the appetite-suppression novelty has plateaued — the body has begun adaptive thermogenesis. The practitioner corpus describes this as "adaptive thermogenesis... the body tries to conserve its energy stores by reducing the number of calories that you burn by downregulating thyroid hormones." That downregulation is not theoretical — it shows up as falling fT3, rising rT3, and a resting metabolic rate that drops faster than your scale weight would predict.
Second, the substrate cites a reproducible pattern: free fatty acids flooding the bloodstream during rapid fat mobilization "temporarily worsen insulin sensitivity" — meaning fasting glucose and HOMA-IR can look worse at Week 10 in a clear responder than at baseline. This is mechanistically expected during aggressive fat loss and resolves as fat mass declines, but it confuses anyone reading the numbers without the trajectory.
Third, lean body mass attrition. The substrate is explicit that GLP-1 monotherapy (especially semaglutide, which lacks GIP agonism) drives meaningful LBM loss. Tirzepatide partially offsets this through GIP-driven nutrient partitioning toward muscle. Retatrutide adds glucagon agonism — the only mechanism in this class that "forces the body to mobilize and burn stored fat" via hepatic fat oxidation, the pathway unique to triple agonism. Where you sit on this single-agonist → dual → triple ladder determines what's recoverable at Week 10.
The classification logic:
- Clear responder — weight down 10-15%+, waist circumference tracking with weight loss, fT3 holding within 15% of baseline, energy stable, DEXA (if available) shows ≤25% of loss from LBM.
- Partial responder — weight down 5-10%, but waist not moving in proportion (visceral-only loss has stalled), fT3 dropped >20%, evening cortisol elevated, training capacity has measurably degraded.
- Non-responder — weight down <5%, or weight stable while LBM has dropped (recomposition in the wrong direction), or weight loss arrested entirely by Week 6 and held flat through Week 10.
Scenario A: Clear responder — protect what's working, don't dose-stack
The mistake here is escalation reflex. The protocol is working. The substrate is direct: find the minimum effective dose that keeps fat loss moving in the right direction. Hold or trim. Layer protection, not aggression.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tirzepatide (continue) | 7.5-10 mg | SubQ | Weekly | Clinical 🔵 | Hold dose if responding; do NOT escalate past minimum effective |
| CJC-1295 (no DAC) + Ipamorelin | 100 mcg + 200-300 mcg | SubQ | 5 nights/week, pre-bed | Expert 🟢 | LBM preservation; pulsatile GH support |
| MOTS-c | 5-10 mg | SubQ | 2-3×/week | Expert 🟢 | Mitochondrial efficiency under sustained deficit; substrate ties this to AMPK/metabolic flexibility |
| Refeed protocol | +500-800 kcal carbs | Oral | 1 day every 14 days | Expert 🟢 | Substrate calls for refeed at least once every 4 weeks under sustained deficit; bias to 2 weeks if responding hard |
| Protein floor | 1 g/lb LBM | Oral | Daily | Expert 🟢 | Non-negotiable — substrate explicit on appetite suppression making this hard to hit |
Scenario B: Partial responder — pivot to mechanism, not dose
This is the most common Week 10 shape and the most misread. Weight is moving but body composition is degrading: fT3 has dropped, waist isn't tracking, training is harder. The lever isn't more GLP-1 — it's the suppressed downstream axes.
The substrate frames this clearly: under deficit, the body shifts pregnenolone toward cortisol production at the expense of progesterone and sex hormones ("pregnenolone steal"), reverse T3 climbs to block T3 action, and the thyroid axis effectively idles. Adding GLP-1 dose on top of an idling thyroid is pushing harder on a parking brake.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tirzepatide (hold or trim) | 5-7.5 mg | SubQ | Weekly | Clinical 🔵 | Do not escalate — the limiter is downstream |
| T3 (liothyronine) | 5-12.5 mcg | Oral | AM, empty stomach | Expert 🟢 | Substrate consistent: "with reverse T3 issue, lower the T4 or do just T3"; titrate to fT3 mid-range, not TSH |
| MOTS-c | 10 mg | SubQ | 3×/week | Expert 🟢 | Mitochondrial restoration; substrate ties this to recovering metabolic rate under chronic deficit |
| 2-week diet break | Maintenance kcal | Oral | 14 contiguous days | Expert 🟢 | MATADOR-style break — substrate describes this as resetting leptin and ending the rebound trap |
| Adaptogen layer (rhodiola, ashwagandha) | Standard label doses | Oral | Daily | Expert 🟢 | Cortisol normalization while thyroid recovers |
| 5-Amino-1MQ | 50-150 mg | Oral | Daily | Experimental 🟣 | NNMT inhibition; substrate cites fat reduction + appetite suppression without GLP-1 mechanism stacking |
The diet break is the load-bearing move. Hold tirzepatide flat, eat at maintenance for 14 days, let fT3 recover, then re-enter deficit. The substrate is explicit that this is not "cheating the protocol" — it's the protocol.
Scenario C: Non-responder — switch the receptor profile
If Week 10 weight is <5% down or LBM has fallen while fat hasn't, the issue isn't compliance and isn't dose. The receptor profile is wrong for this patient. Semaglutide-class monoagonism may not be enough. Tirzepatide may not be enough. The substrate's framing: single-receptor GLP-1 "proved appetite suppression could drive fat loss"; dual GLP-1/GIP "added muscle nutrient partitioning"; retatrutide's glucagon arm "forces the body to mobilize and burn stored fat... the pathway unique to retatrutide."
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Retatrutide (transition from tirzepatide) | Start 2 mg, titrate to 4-8 mg | SubQ | Weekly | Clinical 🔵 (Phase 2/3) | Substrate cites cautious titration; allow 1-week washout between final tirz dose and first reta dose |
| Electrolyte protocol | Na+, K+, Mg2+ to label dose | Oral | Daily | Expert 🟢 | Substrate explicit on cardiac arrhythmia / cramping / cognition risk on retatrutide without aggressive electrolytes |
| Protein floor | 1 g/lb LBM | Oral | Daily | Expert 🟢 | Substrate frames protein as non-negotiable: "Retatrutide suppresses appetite aggressively — you must be intentional" |
| Clean carbs around training | 30-50 g | Oral | Pre/post training only | Expert 🟢 | Substrate: "Running a zero-carb diet on retatrutide undermines the compound's mechanism" |
| CJC-1295 + Ipamorelin | 100 mcg + 200 mcg | SubQ | 5 nights/week | Expert 🟢 | LBM preservation through receptor switch |
| BPC-157 | 250-500 mcg | SubQ | Daily, 4 weeks | Expert 🟢 | GI tolerance support during reta titration |
This is not a cosmetic change. The transition is a mechanism switch — you are no longer treating "insufficient appetite suppression," you are treating "insufficient hepatic fat oxidation." Expect transient insulin resistance markers during the first 4-6 weeks of retatrutide as free fatty acids mobilize. The substrate is explicit that this is expected and resolves as fat mass declines.
What's NOT happening yet (set this correctly)
- Scale weight is not the trajectory marker. Waist circumference, fT3, and DEXA-derived LBM are the leading indicators. Weight is lagging and noisy.
- HOMA-IR / fasting glucose may worsen mid-protocol. Free fatty acid flooding during rapid lipolysis temporarily raises these — substrate-cited and expected.
- TSH is the wrong thyroid marker here. Under suppression dieting, TSH stays artificially normal while fT3 collapses and rT3 climbs. Read fT3 and rT3, ignore TSH.
- A diet break is not a setback. The 14-day maintenance window is the mechanism — leptin recovery, thyroid recovery, cortisol normalization. The next deficit phase will move faster because of it.
- Dose escalation is not the universal answer. Two of the three Week 10 shapes (clear responder, partial responder) require holding or trimming GLP-1 dose, not pushing it.
Research describes these three shapes. Track which one you are. Adjust the lever the substrate actually points at, not the one closest to hand.